CDK4/6 Inhibitors & Toxicities: Collaborative Pharmacy Management

Okay, here’s a breakdown of the provided text, focusing on the key facts from the interview with Heather Moore, PharmD, BCOP, CPP, regarding CDK4/6 inhibitors in ⁢HR+/HER2- breast cancer therapy:

Key Points:

* CDK4/6 Inhibitors as Backbone of Therapy: CDK4/6 inhibitors (palbociclib, abemaciclib, and ribociclib) are central to the treatment of hormone receptor-positive (HR+), HER2-negative⁤ metastatic ⁢breast cancer due to demonstrated improvements ⁢in ⁤both progression-free survival (PFS) and overall survival (OS). ⁢ This is supported ⁣by ⁣data from clinical trials like MONARCH, MONALEESA, and PALOMA, ⁢and⁤ also real-world evidence.
* Drug-Drug Interaction ⁣Management: Managing drug-drug interactions with CDK4/6 inhibitors is ‍crucial, and requires consideration of both:
⁣* Pharmacokinetic (PK) Interactions: ⁢All three inhibitors are CYP3A4 substrates. Ribociclib⁢ is also a CYP3A4 inhibitor. ⁤This means potential for altered drug levels and the need for dose adjustments or alternative drug selection.
*‍ Pharmacodynamic (PD) Interactions: Overlapping toxicities need ⁣to be considered. ‍Specifically, ribociclib ⁤can cause QT⁤ prolongation, which can be worsened by other medications patients may be taking⁢ for⁣ supportive care (pain, ⁢anxiety, depression, etc.).

In essence, the interview highlights the efficacy ⁣of CDK4/6 inhibitors and the importance of careful medication management‍ due to potential drug interactions.

Let me know‍ if you’d like⁤ me to‍ elaborate on any specific aspect of this information!